Wedbush starts Solid Biosciences at Outperform on ‘potentially better’ DMD tool

As previously reported, Wedbush initiated coverage of Solid Biosciences (SLDB) with an Outperform rating and $16 price target First-generation gene therapy in Duchenne muscular dystrophy provides a new treatment opportunity, but “still leaves room for improvement,” says the analyst, who sees Solid’s strategy and novel capsid offering “a potentially better microdystrophin delivery tool.” The firm’s current estimates assign credit solely for SGT-003 in DMD, but it notes that the pipeline offers “additional shots on goal.”